Evidence map›Paper›PMID 32900727›Full record

ArticleBMJ case reports2020

Use of rituximab in lymphomatoid granulomatosis with isolated central nervous system involvement.

Jesse Mooneyham, Cesar Gentille, Andrea Barbieri, Shilpan Shah

Open access · greenAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ case reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 87% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Jesse MooneyhamTexas A&M Health Science Center College of Medicine, Houston, Texas, USA.ORCID http://orcid.org/0000-0001-8501-9066
Cesar GentilleHouston Methodist Cancer Center, Houston, Texas, USA cgentillesanchez@houstonmethodist.org.ORCID http://orcid.org/0000-0001-7643-8154
Andrea BarbieriDepartment of Hematopathology, Houston Methodist Hospital, Houston, Texas, USA.
Shilpan ShahHouston Methodist Cancer Center, Houston, Texas, USA.
Houston Methodist · USMethodist Hospital · USTexas A&M Health Science Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 33-year-old woman presented to the emergency room with severe headaches. A CT scan of the head revealed two brain lesions with associated vasogenic oedema. Diagnostic resection of one of the lesions followed by pathological analysis revealed grade III lymphomatoid granulomatosis (LYG). Staging investigations elsewhere in the body were negative, isolating this case of LYG to the central nervous system, an atypical presentation. After the resection, she was treated with single-agent rituximab 375 mg/m

Indexed as

AdultAntineoplastic Agents, ImmunologicalBrain NeoplasmsFemaleHumansLymphomatoid GranulomatosisRituximabAntineoplastic Agents, ImmunologicalRituximabhaematology (drugs and medicines)malignant and benign haematologymalignant disease and immunosuppressionneurooncologyneurosurgery

Identifiers

PMID32900727
PMCPMC7478030
OpenAlexW3083952409

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.